TrialNeuro-oncology2023

Phase II study of intrathecal administration of trastuzumab in patients with HER2-positive breast cancer with leptomeningeal metastasis.

Florence Oberkampf et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.